摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-Pyridin-2-ylpiperazin-1-yl)acetamide | 697282-55-6

中文名称
——
中文别名
——
英文名称
2-(4-Pyridin-2-ylpiperazin-1-yl)acetamide
英文别名
——
2-(4-Pyridin-2-ylpiperazin-1-yl)acetamide化学式
CAS
697282-55-6
化学式
C11H16N4O
mdl
MFCD05147258
分子量
220.27
InChiKey
YFPGQTMHZHRFCO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.454
  • 拓扑面积:
    62.5
  • 氢给体数:
    1
  • 氢受体数:
    4

文献信息

  • Isoxazole Derivatives and Use Thereof
    申请人:Cho Jeong Woo
    公开号:US20090131336A1
    公开(公告)日:2009-05-21
    Disclosed herein are isoxazole derivaties and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt/β-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed.
    本文披露了异噁唑衍生物及其用途。作为Wnt的激动剂,异噁唑衍生物激活Wnt/β-连环蛋白信号传导,因此可用于治疗和预防与信号传导相关的疾病。此外,还披露了异噁唑衍生物的药用盐。
  • Pyrimidine A2B selective antagonist compounds, their synthesis and use
    申请人:Castelhano Arlindo
    公开号:US20050119271A1
    公开(公告)日:2005-06-02
    The subject invention provides compounds having the structure: wherein R 1 is substituted or unsubstituted phenyl or a 5-6 membered heterocyclic or heteroaromatic ring containing from 1 to 5 heteroatoms; R 2 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)-O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety; R 3 is hydrogen, or a substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)-O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R 2 and R 3 are joined to form a heterocyclic ring; wherein the dashed line represents a second bond which may be present or absent, and when present R 3 is oxygen; R 4 and R 5 are each independently substituted or unsubstituted alkyl, —C(O)-alkyl, —C(O)-O-alkyl, alkoxy, cycloalkyl, alkenyl, monocyclic or bicyclic aryl, heteroaryl or heterocyclic moiety, or R 4 NR 5 together form a substituted or unsubstituted monocyclic or bicyclic, heterocyclic or heteroaryl moiety containing from 1 to 6 heteroatoms; R 12 is hydrogen, alkyl, halogen or cyano; and n is 0, 1, 2, 3 or 4, or an enantiomer, or a specific tautomer, or a pharmaceutically acceptable salt thereof and a method for treating a disease associated with the A 2b adenosine receptor by administering a therapeutically effective amount of the compounds of the invention.
    本发明提供具有以下结构的化合物: 其中,R1是取代或未取代的苯基或含有1至5个杂原子的5-6元杂环或杂芳基环;R2是氢,或取代或未取代的烷基,-C(O)-烷基,-C(O)-O-烷基,烷氧基,环烷基,烯基,单环或双环芳基,杂芳基或杂环基;R3是氢,或取代或未取代的烷基,-C(O)-烷基,-C(O)-O-烷基,烷氧基,环烷基,烯基,单环或双环芳基,杂芳基或杂环基;或R2和R3结合形成杂环环;其中虚线表示第二键可能存在或不存在,当存在时,R3是氧;R4和R5分别是取代或未取代的烷基,-C(O)-烷基,-C(O)-O-烷基,烷氧基,环烷基,烯基,单环或双环芳基,杂芳基或杂环基;或R4NR5一起形成含有1至6个杂原子的取代或未取代的单环或双环,杂环或杂芳基;R12是氢,烷基,卤素或氰基;n为0、1、2、3或4,或其对映异构体,或其特定互变异构体,或其药学上可接受的盐,并提供了一种通过给予本发明化合物的治疗有效量来治疗与A2b腺苷受体相关的疾病的方法。
  • Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
    申请人:Anikin Alexey Vyacheslavovich
    公开号:US20080207635A1
    公开(公告)日:2008-08-28
    The present invention provides compounds capable of modulating tyrosine kinases, compositions comprising the compounds and methods of their use.
    本发明提供了能够调节酪氨酸激酶的化合物,包括这些化合物的组合物和使用它们的方法。
  • Renin-inhibitory oligopeptides, their preparation and use
    申请人:SANKYO COMPANY LIMITED
    公开号:EP0228192A2
    公开(公告)日:1987-07-08
    Oligopeptides of formula (I): where R1R7 are various organic groups and n and m are 0 or 1, have renin-inhibitory activity and are particularly suitable for oral administration. They may be prepared by condensing their component amino acids or lower oligopeptides using conventional peptide synthesis reactions.
    式(I)的寡肽: 其中 R1R7 为各种有机基团,n 和 m 为 0 或 1,具有肾素抑制活性,特别适合口服。它们可以通过传统的肽合成反应缩合其氨基酸组分或低级寡肽来制备。
  • PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE
    申请人:OSI Pharmaceuticals, Inc.
    公开号:EP1465631A2
    公开(公告)日:2004-10-13
查看更多